Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
TDW	1	5,252,714		Harris et al.	10-12-1993	
	2	5,264,563		Huse	11-23-1993	
	3	5,338,665		Schatz Et al	08-16-1994	
	4	5,348,867		Georgiou et al.	09-20-1994	
	5	5,470,725		Borriss et al.	11-28-1995	
	6	5,512,463		Georgiou et al.	09-20-1994	
	7	5,514,588		Varadaraj	05-07-1996	
	8	5,523,388		Huse	06-04-1996	
	9	5,571,698		Ladner et al.	11-05-1996	
	10	5,589,466		Felgner et al.	12-31-1996	
	11	5,593,972		Weiner et al.	01-14-1997	
	12	5,605,793		Stemmer et al	02-25-1997	
	13	5,691,170		Gritz et al.	11-25-1997	
	14	5,698,426		Huse	12-16-1997	
	15	5,703,057		Johnston et al.	12-30-1997	
	16	5,723,323		Kauffman et al.	03-03-1998	
	17	5,763,192		Kauffman et al.	06-09-1998	
	18	5,763,239		Short et al.	06-09-1998	
	19	5,770,434		Huse	06-23-1998	
	20	5,783,386		Jacobs, Jr. et al.	07-21-1998	
	21	5,789,228		Lam et al.	08-04-1998	
	22	5,808,022		Huse	09-15-1998	
↓	23	5,811,238		Stemmer et al.	09-22-1998	

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW	24	5,814,473		Warren et al.	09-29-1998	
	25	5,814,476		Kauffman et al.	09-29-1998	
	26	5,817,483		Kauffman et al.	10-06-1998	
	27	5,824,469		Horwitz et al.	10-20-1998	
	28	5,824,514		Kauffman et al.	10-20-1998	
	29	5,830,696		Short	11-03-1998	
	30	5,830,721		Stemmer et al.	11-03-1998	
	31	5,834,252.		Stemmer et al	11-10-1998	
	32	5,837,458		Minshull et al.	11-17-1998	
	33	5,862,514		Kauffman et al.	10-20-1998	
	34	5,866,344		Georgiou	02-02-1999	
	35	5,866,363		Pieczenik	02-02-1999	
	36	5,871,974		Huse	02-16-1999	
	37	5,876,997		Kretz	03-02-1999	
	38	5,882,883		Egel-Mitani et al.	03-16-1999	
	39	5,925,749		Mathur, et al.	07-20-1999	
	40	5,928,905.		Stemmer et al	07-27-1999	
	41	5,939,250		Short	08-17-1999	
	42	5,939,300		Robertson, et al.	08-17-1999	
	43	5,942,430		Robertson, et al.	08-24-1999	
	44	5,948,666		Callen, et al.	09-07-1999	
	45	5,955,358		Huse	09-21-1999	
	46	5,958,672		Short	09-28-1999	
	47	5,958,751		Murphy, et al.	09-28-1999	
✓	48	5,962,258		Mathur, et al.	10-05-1999	

Examiner Signature	T. Wessendorf	Date Considered	9/5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW		49	5,965,408		Short	10-12-1999	
		50	5,962,283		Warren et al.	10-05-1999	
		51	5,976,862		Kauffman et al.	11-02-1999	
		52	5,985,285		Titball et al.	11-16-1999	
		53	5,985,646		Murphy, et al.	11-16-1999	
		54	5,989,553		Johnston, et al.	11-23-1999	
		55	6,001,574		Short et al.	12-14-1999	
		56	6,004,788		Short	12-21-1999	
		57	6,030,779		Short	02-29-2000	
		58	6,043,030		Beach et al.	03-28-2000	
		59	6,054,267		Short	04-25-2000	
		60	6,054,312		Lacocca et al.	04-25-2000	
		61	6,057,103		Short	12-21-1999	
		62	6,087,341		Khavari et al.	07-11-2000	
		62A	6,096,548		Stemmer	08-01-2000	
		63	6,117,679		Stemmer	9-12-2000	
		64	6,132,970		Stemmer	10-17-2000	
		65	6,153,410		Arnold et al.	11-28-2000	
		66	6,156,511		Schatz et al.	12-05-2000	
		67	6,159,687		Vind	12-12-2000	
		68	6,159,688		Borchert et al.	12-12-2000	
		69	6,165,718		Borchert et al.	12-26-2000	
		70	6,165,793		Short	12-26-2000	
		71	6,168,919		Short	01-02-2001	
✓		72	6,171,820		Short et al.	01-09-2001	

Examiner Signature	T. Murphy	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	73	6,174,673		Short et al.	01-16-2001		
	74	6,177,263		Arnold et al.	01-23-2001		
	75	6,180,406		Stemmer et al.	01-30-2001		
	76	6,194,183		Markvardsen et al.	02-27-2001		
	77	6,238,884		Short et al.	05-29-2001		
	78	6,251,674		Tobin et al.	06-26-2001		
	79	6,261,561		Stewart, Jr. et al.	07-17-2001		
↓	80	6,287,861		Stemmer et al.	09-11-2001		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document: Office	Foreign Patent Document: Number	Foreign Patent Document: Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
TW	81	EP	0 125 228	A1	President and Fellows of Harvard College	06-15-1988		
	82	EP	0554809	B1	Ixsys, Inc.	12-16-1998		
	83	EP	0563296	B1	Ixsys, Inc.	03-17-1999		
	84	EP	0 725081	A1	Kyowa Hakko Kogyo Co., Ltd.	08-07-1996		
	85	EP	0 752008	B2	Maxygen, Inc.	02-17-1995		
	86	EP	0876509	B1	Maxygen, Inc.	09-19-2001		
	87	EP	0911396	A2	Stemmer	04-28-1999		
	88	EP	0911396	A3	Stemmer et al.	05-06-1999		
	89	EP	0934999	A1	Stemmer et al.	08-11-1999		
↓	90	WO	90/14424		Scripps Clinic and Research	11-29-1990		

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

					Foundation			
TdW	91	WO	90/14443		Huse	11-29-1990		
	92	WO	91/07979		Center for Innovative Technology	06-13-1991		
	93	WO	92/03461		Ixsys, Inc.	03-05-1992		
	94	WO	92/06176		Ixsys, Inc.	04-16-1992		
	95	WO	92/06204		Ixsys, Inc.	04-16-1992		
	96	WO	92/11272		Ixsys, Inc	07-09-1992		
	97	WO	93/06214		The United States of America	04-01-1993		
	98	WO	93/10214		Georgiou	05-27-1993		
	99	WO	94/06421		The University of Tennessee Research	03-31-1994		
	100	WO	94/06911		Board of Regents, The University of Texas System	03-31-1994		
	101	WO	94/11496		Ixsys, Inc.	05-26-1994		
	102	WO	94/23738	A1	Medisorb Technologies International L.P.	10-27-1994		
	103	WO	94/25608		Baylor College of Medicine	11-10-1994		
	104	WO	94/26787	A1	The Boead of Trustees of the Leland Stanford Junior University	11-24-1994		
	105	WO	95/22625		Stemmer et al.	08-24-1995		
V	106	WO	95/16027	A1	Borrebaeck	06-15-1995		

Examiner Signature	T. Wendel	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW	107	WO	95/26718		Apollon, Inc.	10-12-1995		
	108	WO	96/11279	A1	US Department of Health and Human Services	04-18-1996		
	109	WO	96/13250	A1	Amgem, Inc.	05-09-1996		
	110	WO	96/23882		The Rockefeller University	08-08-1996		
	111	WO	96/31613		Board of Regents	10-10-1996		
	112	WO	96/33207		Glaxo Group Limited	10-24-1996		
	113	WO	96/37624		MG-PMC, L.L.C.	11-28-1996		
	114	WO	97/04077		Recombinant Biocatalysis, Inc.	02-06-1997		
	115	WO	97/07128	A1	Duke University	02-27-1997		
	116	WO	97/07205		Okkels	02-27-1997		
	117	WO	97/11605	A1	University of Pittsburg of the Commonwealth System of Higher Education	04-03-1997		
	118	WO	97/20078		Stemmer et al.	06-05-1997		
	119	WO	97/25410		Borchert et al	07-17-1997		
	120	WO	97/32987	A1	University of Toronto	09-12-1997		
	121	WO	97/35957	A1	Stemmer	10-02-1997		
	122	WO	97/35966		Maxygen Inc.	10-07-1997		
	123	WO	97/44361		Lam et al.	11-27-1997		
	124	WO	97/48416		Mathur et al.	12-24-1997		
	125	WO	97/48717		Short et al.	12-24-1997		
✓	126	WO	97/48794		Murphy et al.	12-24-1997		

Examiner Signature	T. Wenderoth	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	127	WO	98/00526		Robertson et al.	01-08-1998		
	128	WO	98/01581		Short	01-15-1998		
	129	WO	98/05764		Novo Nordisk	02-12-1998		
	130	WO	98/05765		Novo Nordisk	02-12-1998		
	131	WO	98/13485		Stemmer et al.	04-02-1998		
	132	WO	98/13487		Stemmer et al.	04-02-1998		
	133	WO	98/24799		Bylina	06-11-1998		
	134	WO	98/27230		Patten et al.	06-25-1998		
	135	WO	98/28416		Bjornvad et al.	07-02-1998		
	136	WO	98/31816		Regents of the University of Minnesota	07-23-1998		
	137	WO	98/31837		Delcardayre et al.	07-23-1998		
	138	WO	98/36080		Affholter et al.	08-20-1998		
	139	WO	98/41622		Borchert et al.	09-24-1998		
	140	WO	98/41623		Borchert et al.	09-24-1998		
	141	WO	98/41653		Vind et al.	09-24-1998		
	142	WO	98/42727		SRI International	10-01-1998		
	143	WO	98/42832		Arnold et al.	10-01-1998		
	144	WO	98/45444		The Regents of the University of California	10-15-1998		
	145	WO	98/48034		Neiboer et al.	10-29-1998		
	146	WO	98/49286		Board of Regents, The University of Texas System	11-05-1998		
	147	WO	98/58085		Short et al.	12-23-1998		

Examiner Signature	T. Wszuty	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TOW	148	WO	99/07837		Callen	02-18-1999		
	149	WO	99/08539		Kretz	02-25-1999		
	150	WO	99/10472		Short	03-04-1999		
	151	WO	99/10539		Short	03-04-1999		
	152	WO	99/19506		Ixsys, Inc.	04-22-1999		
	154	WO	99/19518		Short	04-22-1999		
	155	WO	99/21979		Apt et al.	05-06-1999		
	156	WO	99/23107		Stemmer et al.	05-14-1999		
	157	WO	99/23236		Diversa Corp. et al.	05-14-1999		
	158	WO	99/29902		Arnold et al.	06-17-1999		
	159	WO	99/41366		The Board of Trustees of the Leland Stanford Junior University	08-19-1999		
	160	WO	99/41368		Maxygen, Inc.	08-19-1999		
	161	WO	99/41369		Maxygen, Inc.	08-19-1999		
	162	WO	99/41383		Maxygen, Inc.	08-19-1999		
	163	WO	99/41402		Maxygen, Inc.	08-19-1999		
	164	WO	99/45154		Short et al.	09-10-1999		
	165	WO	99/57128		Stemmer et al.	11-11-1999		
	166	WO	99/65927		Maxygen, Inc,	12-23-1999		
	167	WO	00/18778		Phylos, Inc.	04-06-2000		
	168	WO	00/42560		Selifonov et al.	07-20-2000		
	169	WO	00/42561		Crameri et al.	07-20-2000		
	170	WO	00/46344		Diversa Corrporation	08-10-2000		
↓	171	WO	00/53744		Short et al.	09-14-2000		

Examiner Signature	T. Wessendorf	Date Considered	9/9/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW	172	WO	00/58517		Short et al.	10-05-2000		
TDW	173	WO	00/16984		Maxygen, Inc	03-30-2000		
TDW	174	WO	01/00234		Maxygen, Inc	01-04-2001		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
TDW	175	**Affholter et al.** (1998) "Directed evolution of proteins and pathways by DNA shuffling." Book of Adstracts, 216th ACS National Meeting, Boston, August 23-27, BIOT-042	
	176	**Agren et al.** (1997) "Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit." *J. Immunol* 158:3936	
	177	**Ahmed** (1995) *J Bacteriology* 177(14):3904-3910	
	178	**Ahn et al.** (1996) "Human cytomegalovirus inhibits antigen presentation by a sequential multistep process." *Proc. Natl. Acad, Sci USA* 93:10990	
	179	**Aizaki et al.** (1998) "Full-Length Complementary DNA of Hepatitus C Virus Genome From an Infectious Blood Sample." *Hepatology 27:621-627 (1998)*	
	180	**Aldovini & Young** (1991) "Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines." *Nature* 351:479-482	
	181	**Ambriovic, A. et al. (1997)** "Efficacy of Replication-Defective Adenovirus-Vectored Vaccines: Protection Following Intramuscular Injection Is Linked to Promoter Efficiency in Muscle Representative Cells" Virology 238:, 327-335	
	182	**Appel and Harris** (1998) "Antiboby titers in domestic ferret fills and kits to canine distemper virus vaccines." *JAVMA* 193:332-333	
	183	**Atkins et al.** (1996) "Manipulation of the Semliki Forest Virus Genome and Its Potential for Vaccine Construction." *Mol Biotechnol* 5:33-38	
	184	**Attridge et al.** (1997) "Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain." Vaccine 15(2): 155-162	
	185	**Axon** (1998) "Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives." *Gut* 43(1):S70-3	
	186	**Baba et al.,** "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC," The J. of Biolog. Chem. 272 (23): 14893-14898 (1997)	
	187	**Barry et al.** (1994) "Production of monoclonal antibodies by genetic immunization." *Short Technical Reports in Biotechniques* 16(4):616	
	188	**Barry et al.** (1995) "Protection against nycoplasma infection using expression-library immunization." *Nature* 377:632	

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW	189	**Bass et al.** (1990) "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties." *Proteins: Structures, Function and Genetice* 8:309-314	
	190	**Beattie et al.** (1990) "Cloning and characterization of T-cell-reactive protein anigens from Listeria monocytogenes." *Infection and Immunity* 58(9):2792-2803	
	191	**Beck et al.,** "DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing," J. Mol. Biol. 228:433-441 (1992)	
	192	**Behrens et al.** (1996) "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus." *EMBO J.* 15:12-22	
	193	**Benham et al.** (1997) "Proteasome activity limits the assembly f HMC class 1 molecules after IFN-gamma stimulation." *J. Immol* 159(2):5896-5904	
	194	**Berkhout et al.** (1999) "Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type I Vaccine Strains." *J. Virology* 73(2):1138-1145	
	195	**Bernard et al.** (1994) "Transcriptional Control and Cell Type Specificity of HPV Gene Expression." *Arch Dermatol* 130:210	
	196	**Bhatnagar et al.** (1982) "Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant." *Proc Nat'l Acad Sci USA* 79:4400-4404	
	197	**Bielefeldt-Ohmann, H. et al.,** "Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system," J. Gen. Virol. 78:2723-2733 (1997)	
	198	**Blachere et al.,** "Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphyocyte Response and Tumor Immunity," J. Exp. Med. 186:1315-22 (1997	
	199	**Blanchard et al.** (1998) "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins. . ." *J. Gen. Virol* 79:1159-1167	
	200	**Blaser** (1998) "Helicobacter pylori and gastric disease." *BMJ* 316:1507-1510	
	201	**Bloom et al.** (1993) Characterization of Chimeric Full-Length Molecular Clones of Aleutian Mink Disease Parvovirus (ADV) . . ." *J. Virol* 67(10):5976-5988	
	202	**Bolhuis** (1995) *J. Biological Chamistry* 270(3):26092-26098	
	203	**Botstein and Shortle,** "Strategies and Applications of in Vitro Mutagenesis," Science 229:1193-1201 (1985)	
	204	**Boursnell et al.** (1997) "A Genetically Inactivated Herpes Simplex Virus Type 2 (Hsv-2) Vaccine Provides Effective Protection against Primary & Recurrent HSV-2 Disease." *J. Infect. Dis* 175:16-25	
	205	**Bray et al.** (1989) "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengus Virus Encepha;it is." *J. Virol* 63:2853-2856	
	206	**Bridgen and Elliot** (1996) "Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNA's." *Proc. Nat'l Acad. Sci USA* 93:15400-15404	
	207	**Brocke et al.** (1996) "Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein." *Nature* 379:343-346	
	208	**Brubaker** (1991) "The V Antigen of Yersiniae: An Overview." *Current Investigations of the Microbiology of Yersinae* 12:127-133	
	209	**Burger et al.** (1995) *Proc. of thr Amer Assoc. for Cancer Research* 36:522 Abst #3108	
↓	210	**Burke et al.** (1999) "Formulation, Stability and Delivery of Live Attenuated Vaccines for Human Use." *Crit. Rev. Ther Drig. Carrier Syst* 16:1-83	

Examiner Signature	T. Wilson	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW	211	**Burton** (1995) "Phage Display." *Immunotechnology* 1(2):87-94	
	212	**Carroll and Moss** (1997) "Host range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus. . ." *Virology* 238:198-211	
	213	**Carter et al.**, "Improved oligonucleotide site-directed mutagenesis using M13 vectors," Nucl. Acids Res. 13:4431-4443 (1985)	
	214	**Carter,** "Improved Oligonucleotide-Directed Mutagenesis Using M13 Vectors," Methods in Enzymol. 154:382-403 (1987)	
	215	**Carter**, "Site-directed mutagenesis," Biochem. J. 237:1-7 (1986)	
	216	**Casal** (1999) "Use of parvovirus-like particles for vacation and induction of multiple immune response." *Biotechnol Appl. Biochem* 29:-141-150	
	217	**Cathomen et al.** (1998) "A matrix-less measles virus is infectious and extensive cell fusion: consequences for propagation in the brain." *EMBO J.* 17(14):3899-3908	
	218	***Chang, C., et al. (1999)** "Evolution of a cytokine using DNA family shuffling." Nature Biotechnology 17:793-797.*	
	219	**Chen et al.** "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis." *Science* 265:1237-1240	
	220	**Chen et al.,** "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phase peptide library," Proc. Nat'l. Acad. Sci. USA 93:1997-2001 (1996)	
	221	**Chin et al.** (1993) "Functions and Regulation of the Human Miltidrug Resistance Gene." *Adv. Cancer Res.* 60:157-180	
	222	**Choate and Khavari** (1997) "Sustainability of Keratinocyte Gene Transfer and Cell Survival In Vivo." *Human Gene Therapy* 8:895-901	
	223	**Christians, F.C. et al.,** "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," Nature Biotechnology 17:259-264 (1999)	
	224	**Chu et al.** (1995) "A Vaccina Virus-Vectored Hantaan Virus Vaccing Protects Hamsters from Challenge with Hantaan and Seoul Viruses but Not Pumala Virus." *J. Virol* 69:6417	
	225	**Clackson et al.** (1994) "In vitro selection from protein and peptide libraries." *Trends Biotechnol* 12(5): 173-184	
	226	***Coco et al., (2001)** "DNA shuffling method for generating highly recombined genes and evolved enzymes" Nature Biotechnology vol. 19 pp. 354-359*	
	227	**Collman et al.** (1992) "An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1." *J. Virol* 66(12):7517-7521	
	228	**Conry et al.** (1996) "Selected strategies to augment polynucleotide immunization." *Gene Therapy* 3(1):67-74	
	229	**Conry et al.** (1994) "Immune response to a carinoembryonic antigen polynucleotide vassine." *Cancer Res.* 54:1164-1168	
	230	**Coppel et al.** (1993) "idenification of a coda clone encoding a mature blood stage antigen of Plasmodium falciparum by immunization of mice with bacterial lysates." *EMBO Journal* 3)2):403-407	
	231	**Cote et al.** (1986) "Protection of Chimpanzees from Type B Hepatitis by Immunization with Woodchuck Hepatitis Virus Surface Antigen." *J. Virol* 60:895-901	
↓	232	**Courvalin et al.** (1995) "Gene transfer from bacteria to mammalian cells." *C.R. Acad. Sci III* 18:1207-	

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

		1212	
TW	233	**Crabtree** (1998) "Eradication of chronic Helicobacter pylori infection by therapeutic vaccination." *Gut* 43:7-8	
	234	**Craiu et al.,** "Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide," Proc. Nat'l. Acad. Sci. USA 94:10850-10855 (1997	
	235	***Crameri & Stemmer*** *(1993) "10(20)-fold aptamer library amplification without gel purification." Nucleic Acids Research 21(18): 4410*	
	236	***Crameri, A. et al.,*** *"Combinatorial Multiple Cassette Mutagenesis Creates All the Permutations of Mutant and Wild-Type Sequences," Biotechniques 18:194-195 (1995)*	
	237	***Crameri, A. et al.,*** *"Construction and evolution of antibody-phage libraries by DNA shuffling," Nature Medicine 2:100-103 (1996)*	
	238	***Crameri, A. et al.,*** *"DNA shuffling of a family of genes from diverse species accelerates directed evolution," Nature 391:288-291 (1998) (2-287-1PC & 2-251PC)*	
	239	***Crameri, A. et al.,*** *"Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling," Nature Biotechnology 14:315-319 (1996)*	
	240	***Crameri, A. et al.,*** *"Molecular evolution of an arsenate detoxification pathway by DNA shuffling," Nature Biotechnology 15:436-438 (1997)*	
	241	**Cresswell & Hughes,** "Protein degradation: The ins and outs of of the matter,"Curr. Biol. 7:R552-R555 (1997)	
	242	**Cwirla et al.** (1990) "Peptides on Phage: A vast library of peptides for identifying ligands." *Proc. Nat'l Acad Sci USA* 87:6378-6382	
	243	**Davis et al** (1995) "DNA-based immunization." *Molecular and Cell Biology of Human Gene Therapeutics* 5:368-387	
	245	**Davis et al.** (1989) "In vitro Synthesis of Infectious Venezuelar Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant." *Virology* 171:189-204	
	246	**Davis et al.** (1997) "DNA-Based immunization against hepatitis B surface antigen (HBsAg) in Normal and HBsAg-transgenic mice." *Vaccine* 15(8) 849-822	
	247	**Deng et al.** (1997) "Sustainable cutaneous gene delivery." *Nature Biotechnol* 15:1388-1391	
	248	**Devlin et al.** (1990) "Random Peptide Libraries: A Source of Specific Protein Binding Molecules." *Science* 249:404-406	
	249	**Dieu et al.,**"Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med. 188:373-386 (1998)	
	250	**DiMarco et al.** (1997) "Agnostic and antagonistic variants of ciliary neurothrophic Factor (CNTF) Reveal functional differences between mambrean-bound and soluble CNTF Alpha-receptors." *J Biol. Chem.* 272(37):23069-23075	
	251	**Donovan et al.** (1987) "Genes Encoding Spore Coat Polypeptides from Bacillus subtilis." J. Mol Biol *196:1-10*	
	252	**Drabkin et al.** (1996) "Amber Suppression in Mammalian Cells Dependent upon Expression of an Escherichia coli Aminoacyl-tRNA Synthetase Gene." *Mol Cell. Biol.* 16(3):907-913	
↓	253	**Dubois et al.** (1998) "Immunization against Natural Helicobacter pylori Infection in Nonhuman Primates." *Infect. Immun.* 66:4340-4346	

Examiner Signature	T. Wheeldon	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TDW	254	**Dunn** (1996) "Phage display of proteins." *Curr Opin Biotechnology* 7(5):547-553	
	255	**Eghtedarzadeh and Henikoff,** "Use of oligonucleotides to generate large deletions," Nucl. Acids Res. 14:5115 (1986)	
	256	**Engels and Ackermann** (1996) "Pathogenesis of ruminant herpesvirus infections." *Vet Microbiol* 53:3-15	
	257	**Felici, Franco et al.**, "Peptide and protein display on the surface of filamentous bacteriophage," Biotechnol. Annu. Rev. 1:149-83 (1995)	
	258	**Fields et al.**, "Crystal structure of a T-cell receptor B-chain complexed with a superantigen," Nature 384:188-192 (1996)	
	259	**Fox et al.** (1996) "Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia." *Gene Ther* 3:173-178	
	260	**Francisco, Joseph A. et al.**, "Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface," Proc. Nat'l. Acad. Sci. USA 90:10444-10448 (1993)	
	261	**Frankel and Young** (1998) "HIV-1 Fifteen Proteins and an RNA." *Annu. Rev. Biochem* 67:1-25	
	262	**Freeman et al.**, "B7-1 and B7-2 Do Not Deliver Identical Costimulatory Signals, Since B7-2 but Not B7-1 Preferentially Costimulates the Initial Production of IL-4," Immunity 2:523 (1995)	
	263	**Fritz et al.** "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)	
	264	**Fritz et al.** "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)	
	265	**Gaczynska et al.**,"Proteasome Subunits X and Y alter Peptidase Activities in Opposite Ways to the Interferon-γ-induced Subunits LMP2 and LMP7*,J. Biol. Chem. 271:17275-17280 (1996)	
	266	**Galler et al.** (1997) "The Yellow fever 17D vaccine virus: molecular basis of viral attnuation and its use as an expression vector." *J. Med Biol. Res.* 30:157-168	
	267	**Galocha et al.** (1997) "The Active Site of ICP47, a Herpes Simple Virus-encoded Inhibitor of the Major Histocompatibility Complex. . ." *J. Exp. Med* 185:1565-1572	
	268	**Garnett and Grenfell** (1992) "The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster." *Epidemiol. Infect* 108:513-528	
	269	***Gates, C.M. et al., "Affinity Selective Isolation of Ligands from Peptide Libraries Through Display on a lac Repressor 'Headpiece Dimer'" J. Mol. Biol. 255:1-14 (1996)***	
	270	**Geigenmuller et al.** (1997) "Construction of a Genome-Length cDNA Clone for Human Astrovirus Serotype 1 and Synthesis of Infectious RNA Transcrips." *J. Virol* 71:1713-1717	
	271	**Goldman et al.** (1999) Molecular Cloning and Expression of Major Structural Protein. . ." *J. Virol.* 73:4465-4469	
	272	**Gritsun et al.** (1998) "Development and analysis of a tick-bone encephalitis virus infectious clone using a novel and rapid strategy." *J Virol. Methods* 76:109-120	
	273	**Groettrup et al.** "The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome," Proc. Nat'l. Acad. Sci. USA 94:8970-8975 (1997)	
✓	274	**Groettrup et al.**, "A third interferon –γ-induced subunit exchange in the 20S proteasome," Eur. J. Immunol. 26:863-869 (1997)	

Examiner Signature	T. Wilson dy	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	275	**Groux et al.**,"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature 389:737 (1997)	
	276	**Grundstrom et al.**, "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis," "Nucleic Acids Res. 13:3305-3316 (1985)	
	277	**Gualano et al.** (1998) "Identification of a major determinant of mouse neurovirulence of dengue virus typw 2 using stably cloned genomic-length cDNA." *J. Gen. Virol.* 79:437-466	
	278	**Guo et al.** (1998) "Susceptibility to recombination rearrangements of a chimeric plum pox potyvirus genome after insertion of a foreign gene." *Virus Res* 57:183-195	
	279	**Halminen et al.** (1997) "Expression of MXA Protein in Blood Lymphocytes Discriminates between Viral and Bacterial Infections in Febrile Children." *Pediatric Research* 41:647-650	
	280	**Han, Xiaoliang et al.**, "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl. Acad. Sci USA 92:9747-9751 (1995)	
	281	**Hanes, Jozef and Andreas Pluckthun.**, "In vitro selection and evolution of functional proteins by using ribosome display," Proc. Nat'l. Acad. Sci. USA 94(10):4937-42 (1997)	
	282	**Haq et al.** (1995) "Oral Immunization with a Recombinant Bacterial Antigen Produced in Transgenic Plants." *Science* 268:714-716	
	283	**Haralambiev** (1967) "Immunogenicity Studies on a Inactivated IBR Vaccine Administered Into the Nasal Mucosa." *Acta Vet Acad Sci Hung* 26:215-217	
	284	**Harrington et al.** (1992) "An outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant Center." *J. Infect Dis.* 165:987-993	
	285	**HCJ Ertl et al.,** (1996) "Genetic Immunization" *Viral Immunization* Vol. 9, No. 1, pp. 1-9.	
	286	**He et al.**, "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites," Nucl. Acids Res. 25(24):5132-4 (1997)	
	287	**He et al.** (1998) "The Paramyxovirus SV5 Small Hydrobhobic (SH) Protein Is Not Essential for Virus Growth in Tissue Culture Cells." *Virology* 250:30-40	
	288	**Hedstrom et al.** (1994) "Prospects and strategies for development of DNA vaccines against malaria." 59th Forum in Immunology 476-482	
	289	**Hensel and Lubitz** (1997) Vaccination by Aerosols: Modulation of Clearance Mechanism in the Lung." *Behring. Inst. Mitt.* 98:212-219	
	290	**Hilgers et al.** (1990) "Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestional Mucosa." *Pharmaceutical Res.* 7(9):902-910	
	291	**Hill et al.**, "Phage presentation," Mol Microbiol 20(4):685-92 (1996)	
	292	**Hoffman and Banerjee** (1997) "An Infectious Clone of Human Parainfluenza Virus Type 3." *J Virol.* 71:4272-4277	
	293	**Hohol et al.** (1996) "Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a phase III Pivotal Trial." *Ann. N.Y. Acad Sci.* 778:243-250	
	294	**Holzmann, H. et al.**, "Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes," Vaccine 10:345 (1992)	
	295	**Hopkins and Yoder** (1986) "Reversion to Virulence of Chicken-Passaged Infectious Bronchitis Vaccine Virus." *Avain Dis.* 30:221-223	
Y	296	**Hourvitz et al.** (1996) "Reactogenicity and immunogenicity of a new recombinant hepatitis B Vaccine	

Examiner Signature	T. Mercanti	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

		containing Pre S Antigens." *J Virol. Hepatitis* 3:37-42	
TW	297	**Howard** (1998) "Chemistry of the future: Exploitation of the power of biology." Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27, BTEC-045 Apst #: 528494	
	298	**Hristov and Karadjov** (1975) *Vet Med Nauki* 13:5	
	299	**Huang, Sharon K.S. et al.**, "Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients," J. Invest. Dermatol. 111:662-7 (1998)	
	300	**Hui, George S.N. et al.**, "Dominance of Conserved B-Cell Epitopes of the Plasmodium falciparum Merozoite Surface Protein, MSP1, in Blood-Stage Infections of Naïve Aotus Monkeys," Infect. Immun. 64:1502-1509 (1996)	
	301	**Hulskotte at al.** (1998) "Towards an HIV-1 vaccine: lessons from studies in macaque models." *Vaccine* 16:904-915	
	302	**Hurtado et al.** (1996) "Identification of Domains in Canine Parvovirus VP2 Essential for the Accembly of Virus-Like Particles." *J. Virol* 70:5422-5429	
	303	**Iacono-Connors et al.**, Virus Res. 43:125-136 (1996)	
	304	**Irvine, K.R. et al.**, "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases," Journal of Immunology, 156:238-245 (1996)	
	305	**Jia et al.** (1995) "A Novel virant of avain infectious bronchitis virus resulting from recombination among three different strains." *Arch Virol* 140:259-271	
	306	**Jiang et al.** (1999) "Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles." *Vaccine* 17:1005-1013	
	307	**Jiang et al.**, "Subtraction hybridization identified a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression," Oncogene 11:2477 (1995)	
	308	**Jiang et al.**, "The melanoma differentiation associated gene mda-7 suppresses cancer cell growth," Proc. Nat'l. Acad. Sci. USA 93:9160 (1996)	
	309	**Jin et al.** (1998) "Recombinant Human Respiratory Synctial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV." *Virology* 251:206-214	
	310	**Johnston, et al. (1997)** "Genetic to genomic vaccination" Vol. 15, no. 8 pp 808-809	
	311	**Kang et al.** (1999) "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-like Particles." *Biol. Chem* 380:353-364	
	312	**Karandikar et al.**,"CTLA-4: A Negative Regulator of Autoimmune Disease," J. Exp. Med. 184:783 (1996)	
	313	**Keck. Et al.** (1988) "In Vivo RNA-RNA Recombination of Coronavirus in Mouse Brain." *J. Virol.* 62:1810-1813	
	314	**Keenan et al.**,"Lack of Protection following immunisation with H. pylori outer membrane vesicles highlights antigenic differences between H. felis and H. pylori," FEMS Microbiol Lett. 161:21-7 (1998)	
	315	**Khavari, (1997)** " Therapeutic gene delivery to the skin" Molecular Medicine Today, Dec. 1997: 533538	
	316	**Khavari and Krueger** (1997) "Cutaneous Gene Therapy." *Adv Clin Res Dermatologic Clinics* 15(1): 27-35	
↓	317	**Khusmith et al.** (1991) "Protection against malaria by vaccination with sporozoite surface protein 2 plus	

Examiner Signature	T. Wurster	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

		CS protein." *Science* 252:715	
TKd	318	**Kim et al.**, "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen," J. Immunol. 158:816 (1997)	
	319	**Kim, et al.** (1997) "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No. 8 pp 879-883.	
	320	**Kinney et al.** (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53." *Virology* 230:300-308	
	321	**Kinney et al.**, "Recombinant Vaccinia Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998)	
	322	**Kleanthous et al.**, "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998)	
	323	**Klinman et al.**, "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon □," Proc. Nat'l. Acad. Sci. USA 93:2879 (1996)	
	234	**Klinman, D.M. et al.**, "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 158:3635-3639 (1997)	
	235	**Kobayashi et al.**,"Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989)	
	236	**Kobyashi, Yuzuru et al.**, "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984)	
	237	**Kochel, Tadeusz et al.**, "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997)	
	238	**Kodama et al.**, "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990)	
	239	**Konishi et al.**,"A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prM, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology 190:454 (1992)	
	240	**Koopman et al.**, "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997)	
	241	**Kramer and Fritz**, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," Methods in Enzymol. 154:350-367 (1987)	
	242	**Kramer et al.** "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988)	
	243	**Kramer et al.**, "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984)	
	244	**Kramer et al.**, "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984)	
	245	**Krieg et al.**, "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995)	
	246	**Krieger, M. et al.**, "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992)	
✓	247	**Kruse et al.**, "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement," EMBO J. 11:3237-3244 (1992)	

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	248	**Kuchroo et al.**, "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707 (1995)	
	249	**Kunkel et al.**,"Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Methods in Enzymol. 154:367-382 (1985)	
	250	**Kunkel**, "The efficiency of oligonucleotide directed mutagenesis" Nucleic acids & Molecular Biology 2: 124-135 (1988)	
	251	**Kunkel**, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Proc. Nat'l. Acad. Sci. USA 82:488-492 (1985)	
	252	**Lagranderie et al.** (1993) "BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route." *Tubercle and Lung Disease* 74:38-46	
	253	**Lai et al.** (1991) "Infectious RNA transcribed from stabily cloned full-length cDNA of dengue type 4 Virus." *Proc. Nat'l Acad. Sci. USA* 88:5139-5143	
	254	**Lanar et al.** (1996) "Attanuated Vaccinia Virus-Circumsporoziote Protein Recombinants Confer Protection against Rodent Malaria." *Infect Immun* 64:1666-1671	
	255	**Lanciotti et al.** (1994) "Molecular evolution and epidemology of dengue-3 viruses." *J Gen Virol.* 75:65-75	
	256	**Laud et al.**, Human Immunol. 50:91-102 (1996)	
	257	**Larsen et al.**, Long Term acceptance of Skin and Cardiac Allografts After Blocking CD40 and CD28 Pathways,"Nature 381: 434 (1996).	
	258	**Leary et al.**,"Active Immunization with Recombinent V Antigen from Yersinia Pestis Protects Mice against Plague," Infect. Immun. 3:2854 (1995)	
	259	**Lee et al.**, (1997) "Generation of an Infectious cDNA of a highly cardiovirulent coxsakievirus B3(CVB3m) and comparasion to other infectious CVB cDNAs." *Virus Res* 50:255-235	
	260	**Lee et al.**, "Optimal Induction of Hepatitis C Virus Envelope-Specific Immunity by Bicistronic Plasmid DNA Inoculation with the Granulocyte-Macrophage Colony-Stimulating Facter Gene," J. Virol 72:8430-6 (1998)	
	261	**Lehrer et al.** (1998) "Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis." *FEMS Immunol. Med. Mircobiol.* 21:71-77	
	262	**Leung et al.** (1989) *Technique* 1(1):11-15	
	263	**Li et al.** (1997) "Expression of the Human Papillomavirus Type 11 L1 Capsid Protein in Escherichia coli. . ." *J. Virol* 71(4):2988-2995	
	264	**Li et al.**,"Cloning and functional characterization of a subunit of the transporter associated with antigen processing," Proc. Natl. Acad. Sci USA 94: 8708-8713 (1997).	
	265	**Liao et al.** (1990) *Gene* 107-111	
	266	**Liao et al.**, STRL22 is a Receptor for the CC Chemokine MIP-3α," Biochem. and Biophys. Comms. 236: 212-217 (1997).r	
	267	**Liblau et al.** "Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific autoimmune diseases," Immunol. Today 16:34-38 (1995)	
↓	268	**Liem et al.** (1994) *Nucleic Acids Res* 22(9):1613-1619	

Examiner Signature	T. Wurendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	269	**Lieschke et al.**,"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," Nature Biotech. 15:35 (1997)	
	270	**Limbach and Paoletti** (1996) "Non-replicating expression vectors: applications in vaccine development and gene therapy." *Epidemol. Infect.* 116:241-256	
	271	**Lowe et al.** (1997) "Human Papillamavirus Typw 2 (HPV-11) Nutralizing Antibobies in the Serum and Genitial Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like particles Expressed in Yeast." *J. Invect Dis* 176:1141-1145	
	272	**Lowman, Henry B. and Jame A. Wells,** "Affinity Maturation of Human Growth Hormone by Monovalent Phage Display," J. Mol. biol. 234:564-578 (1993)	
	273	**Lowman, Henry B. and James A. Wells,** "Monovalent Phage Display: A Method for Selecting Variant Proteins from Random Libraries," Methods: A Companion to Methods Enz. 3(3):205-216 (1991)	
	274	**Lu, Zhijian et al.**, "Expression of Thioredoxin Random Peptide Libraries on the Escherichia coli Cell Surface as Functional Fusions to Flagellin: A System Designed for Exploring Protein-Protein Interactions," Bio/Technology 13:366-372 (1995)	
	275	**Luytjes et al.** (1989) "Amplification, Expressionand Packaging of a Foreign Gene by Influenza Virus." *Cell* 59:1107-1113	
	276	**MacKay et al.** (1981) "Production of immunology active surface of hepatitis B virus by Escherichia coli." *Proc. Natl. Acad. Sci USA* 78:4510-4514	
	277	**Mandl et al.** (1997) "Infectious cDNA clones of tick-borne encephalitis virus European subtype protopic strain Neudoerfl and high virulence strain Hypr." *J. Gen. Virol* 78:1049-1057	
	278	**Marchetti, Marta et al.**, "Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant," Vaccine 16:33-7 (1998)	
	279	**Marusina et al.**,"Allelic Variation in the Mouse Tap-1 and Tap-2 Transporter Genes," J. Immunol. 158:5251-5256 (1997)	
	280	**Mattheakis, Larry C. et al.**, "An in vitro polysome display system for identifying ligands from very large peptide libraries," Proc. Nat'l. Acad. Sci. USA 91(19):9022-6 (1994)	
	281	**McAtee, C. Patrick et al.**, "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter pylori by "Proteome" Technologies," Helicobacter 3:163-9 (1998)	
	289	**McAtee, C. Patrick et al.**, "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter pylori by Two-Dimensional Gel Electrophoresis, Sequence Analysis, and Serum Profiling," Clin. Diagn. Lab. Immunol. 5:537-42 (1998)	
	290	**McCutcheon et al.** "A senstive ELISPOT assay to detect low-frequency human T lymphocytes,", J. Immunol. Methods 210:149-66 (1997)	
	291	**McGregor, Duncan,** "Selection of Proteins and Peptides from Libraries Displayed on Filamentous Bacteriophage," Mol Biotechnol. 6(2):155-62 (1996)	
	292	**Melen et al.,** "Enzymatic Characterization of Interferon-Induced Antiviral GTPases Murine Mx1 and Human MxA Proteins," J. Biol, Chem. 269: 2009-2015 (1994).	
	293	**Mendoza, R.B. et al.** (1997) "Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization" J. Immunol Dec. 15;159(12):5777-81 ABSTRACT ONLY	
↓	294	**Metz et al.** (1996) "Bicistronic and Two-Gene Retroviral Vectors for Using MDR1 as a Selectable Market and a Therapeutic Gene." *Virology* 217:230-241	

Examiner Signature	T. Wong	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	295	**Meulenberg et al.** (1998) "An Infectious cDNA Clone Porcine Reproductive and Respiratory Syndrome Virus." *Coronaviruses and Arteriviruses* 440:199-206	
	296	**Meulenberg et al.** (1998) "Infectious Transcrips from Cloned Genome-Length cDNA of Porcine Reproductive and Respiratory Syndrome Virus." *J. Virol.* 72:380-387	
	297	**Meyer et al.** (1998) "Bovine herpesvirus type 1 glycoprotein H is essential for penetration and and propagation in cell culture." *J. Gen Virol.* 79:1983-1987	
	298	***Minshull, J. and Willem P.C. Stemmer,*** *"Protein evolution by molecular breeding," Current Opinion in Chemical Biology 3:284-290 (1999)*	
	299	**Mittelholzer et al.** (1997) "Generation of cytopathogenic RNA of classical swine fevor in persistently infected porcine cell lines." *Virus Res* 51:125-137	
	300	**Monaco**, "Pathways for the processing and presentation of antigens to T cells," J. Leukocyte Biol. 57:543-57 (1995)	
	301	**Morita et al.** (1987) "Recombinant vaccinia virus LC16m0 or LC1m8 that expresses hepatitus B surface antigen while preserving the attention of the parental virus." *Vaccine* 5:65-70	
	302	**Mosmann and Coffman**, Adv. Immunol. 46:111 (1989)	
	303	**Moss** (1994) "Replicating and Host-Restricted Non-Replicating Vaccina Virus Vectors for Vaccine Development." *Dev. Biol. Stand* 82:55-63	
	304	**Mundt and Vakharia** (1996) "Synthetic transcripts of double-stranded Birnavirus genome are infectious." *Proc Nat'l Acad. Sci USA* 93:11131-11136	
	305	**N. Miller et al.**, (1995) "Targeted vectors for gene therapy," FASEB J., 9, pp. 190-199.	
	306	**Nakamaye and Eckstein,** "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis," Nucl. Acids Res. 14:9679-9698 (1986)	
	307	**Nambiar et al.**,"Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," Science 223:1299-1301 (1984)	
	308	**Nazerian et al.** (1996) "Protection and synerhism by Recombinant Fowl Pox Vaccines Expressing Genes from Marek's Disease Virus." *Avian Dis.* 40:368-376	
	309	**Nemoto, Naoto et al.**, "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro," FEBS Lett. 414(2):405-8 (1997)	
	310	***Ness, J. et al., (1999)*** *"DNA shuffling of subgenominc sequences of subtilisin." Nature Biotechnology 17:893-896.*	
	311	**Neurath, A.R. et al.**, "Monoclonal Antibodies to Hepatitis BSurface Antigen (HBsAg) with Anti-a Specificity Recognize A Synthetic Peptide Analogue (S135-155) with Unmodified Lysine (141)," J. Virol. Methods 9:341-346 (1984)	
	312	**Ni and Barrett**, "Nucleotide and deduced amino acid sequence of the structural protein genes of Japanese encephalitis viruses from different geographical locations,"J. Gen. Virol. 76:401 (1995)	
	313	**Notka et al.** (1999) "Construction and Characterization of Recombinant VLPs and Semliki-Forest Virus Live Vectors for Comparative Evaluation in the SHIV Monkey Model." *Biol Chem* 380:341-352	
	314	**O'Neil, Karyn T. et al.**, "Phage display: protein engineering by directed evolution," Curr. Opin. Struct. Biol. 5(4):443-9 (1995)	
	315	**Oda** Kobe J. Med. Sci. 22:123 (1976)	

Examiner Signature	T. Wessendorf	Date Considered	9/26/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	316	**Oggioni, M.R. and Pozzi, G.**, "A host-vector system for heterologous gene expression in Streptococcus gordonii," Gene 169:85-90 (1996).	
	317	**Orme** (1997) "Progress in the development of new vaccines against tuberculosis." *Int. J. Tuberc. Jung. Dis* 1:95-100	
	318	**Ortmann et al.**,"A Critical Role for Tapasin in the Assembly and Function of Multimeric MHC Class 1-TAP Complexes," Science 277: 1306-1309 (1997).	
	319	**Paoletti et al.** (1995) "Highly Attenuated Poxvirus: HYVAC, ALVAC and TROVAC," *Dev Biol Stand* 84:159-163	
	320	**Park and RajBhandary** (1998) "Tatracycline-Regulated Suppression of Amber Codons in Mammalian Cells." *Mol Cell Biol* 18:4418-4425	
	321	**Parren, Paul W.H.I. et al.**, "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design," Immunol. Lett. 57:105-112 (1997)	
	322	**Parronchi et al.**, "IL-4 and IFN (□ and □) Exert Opposite Regulatory Effects on the Development of Cytolytic Potential by Th1 or Th2 Human T Cell Clones," J. Immunol. 149:2977 (1992)	
	323	**Pascopella et al.** (1994) "Identification of a genomc fragment of Mycobacterium tuberculosis." *Infectious Agents & Disease* 2:282-284	
	324	**Pascopella et al.** (1994) "Use of In Vivo complementation in Mycobacterium tuberculosis to identify a genomic fragment associated with virulence." *Infection & Immunity* 62(4):1313-1319	
	325	**Pasquini S. et al.** (1997) " Cytokines and costimulatory molecules as genetic adjuvants" Immunol Cell Biol Aug: 75(4):397-401 ABSTRACT ONLY	
	326	**Patten, P.A. et al.**, "Applications of DNA Shuffling to Pharmaceuticals and Vaccines," Current Opinion in Biotechnology, 8:724-733 (1997)	
	327	**Paul and Seder,** "Lymphocyte Responses and Cytokines," Cell 76:241 (1994)	
	328	**Paulusma et al.** (1996) "Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene." *Science* 271:1126-1128	
	329	**Pelletier, Joelle N.**, (2001) "A Rachitt for our toolbox" Nature Biotechnology vol. 19, p. 314-315	
	330	**Peng et al.** (1998) "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway." *Virology* 240:147-157	
	331	**Penzes et al.** (1996) "Replication and Packaging of Coronavirus Infectious Bronchitis Defective RNSa Lacking a Long Open Reading Frame." *J. Virol* 70:86660-8668	
	332	**Phizicky, Eric M. et al.**, "Protein-Protein Interactions: Methods for Detection and Analysis," Microbiol Rev. 59(1):94-123 (1995)	
	333	**Pisetsky, D.S.**, "Immune Activation by Bacterial DNA: A New Genetic Code," Immunity 5: 303-310 (1996).	
	334	**Pletnev, A.G. et al.,** Chimeric Tick-Borne Encephalitis and Dengue Type 4 Viruses: Effects of Mutations on Neurovirulence in Mice," J. Virol. 67(8):4956-4963 (1993)	
	335	**Polo et al.** (1999) "Stable alphavirus packaging cell lines for Sidbis virus-and Semlike Forest virus-derived vectors." *Proc Nat'l Acad. Sci USA*> 96:4598-4603	
	336	**Porcelli** (1995) *Adv. Immunol* 59:1	
↓	337	**Powis et al.**,"Polymorphism in a second ABC transporter gene located within the class II region of the human major hisotcompatibility complex,"Proc. Nat'l. Acad. Sci. USA 89:1463-1467 (1996)	

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TM	338	**Premack et al.** (1996) *Nature Med.* 2:1174	
	339	**Pryor et al.** (1998) "Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins." *J. Gen Virol.* 79:2631-2639	
	340	**Punnonen et al** (1998) "Evolution of genetic vaccines by DNA shuffling." Keystone Symposia on Molecular and Cellular Biology, Molecular Aspects of Viral Immunity, Abstract #227, Tamarron, CO, February 16-20, 1998	
	341	**Punnonen et al.** (1997) "Evolution of DNA Vaccine vectors by gene shuffling." The First Gordon Conference on Genetic Vaccines/DNA Vaccines, Plymouth State College, Plymouth, NH, July 20-25, 1997	
	342	**Punnonen et al.** *J. Exp Med.* 185:993-1004	
	343	**Punnonen et al.**, "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells," Proc. Nat'l. Acad. Sci. USA 90:3730 (1993)	
	344	**Puri et al.** (1998) "Complete Nucleotide Sequences Analysis of a Western Pacific Dengue-1 Virus Strain." *Virus Genes* 17:85-88	
	345	**Racke, Michael K. et al.**, "Cytokine-induced Immune Deviation as a Therapy for Inflammatory Autoimmune Disease," J. Exp. Med. 180:1961-66 (1994)	
	346	**Rahden-staron et al.** (1991) *Biochem & Biophy Res. & Commun.* 177(2):597-602	
	347	**Raj and Jones** (1997) "Growth of infectious bronchitis virus vaccines in oviducts derived from oestrogen-treated chicks and embryos." *Vaccine* 15:163-168	
	348	**Reiser et al.**, "Cloning and expression of a cDNA for the T-cell-activating protein TAP," Proc. Nat'l. Acad. Sci. USA 85:2255-2259 (1988)	
	349	**Roden et al.** (1996) "In Vitro Generation and TypeSpecific Neutralization of a Human Papillomavirus Type 16 Viron Pseudotype." *J. Virol.* 70:5875-5883	
	350	**Roggenkamp et al.**, "Passive Immunity to Infection with Yersinia spp. Mediated by Anti-Recombinant V Antigen is Dependent on Polymorphism of V Antigen," Infect. Immun. 65:446 (1997)	
	351	**Roncarolo et al.** "Human T- and B-cell functions in SCID-hu mice," Semin. Immunol. 8: 207 (1996).-	
	352	**Sagazio et al.** (1998) "Antigenic characterization of canine parvovirus strains isolated in Italy." *J. Virol. Methods* 73:197-200	
	353	**Saggio et al.** (1995) "CNFT Variants with increased biological potency and receptor selectivity define a functional site of receptor interaction." *EMBO Journal* 14(13):3045-3054	
	354	**Sakmar and Khorana**, "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), Nucl. Acids Res. 14:6361-6372 (1988)	
	355	**Sanz et al.** (1994) "Genetic heterogeneity of the attachment glycoprotein G among A respiratory syncytial virusus." *Virus Res* 33:203-217	
	356	**Saurmann et al.** (1990) "Molecular Cloning and Characterization of a German HIV-1 Isolate." *AIDS Res. Hum Retroviruses* 6:813-823	
✓	357	**Sayers et al.** "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide,", Nucl. Acids Res. 16:803-814 (1988)	

Examiner Signature	T. Wisnewski	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	357	**Sayers et al.**, "5'-3' Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis," Nucl. Acids Res. 16:791-802 (1988)	
	358	**Schatz, Peter J. et al.**, "[10] Screening of Peptide Libraries Linked to lac Repressor," Methods Enzymol. 267:171-91 (1996)	
	359	**Schmaljohn, A.L. et al.**, "Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis," Nature 297:70 (1982)	
	360	**Schwarz et al.** (1957) "Modification of Infevtious Bovine Rhinotrachetis (IBR) Virus in Tissue Culture and Development of a Vaccine." *Proc Soc Exp. Biol Med.* 96:453-458	
	361	**Schwarz et al.** (1958) "Propagation and Modification of Infactious Bovine Rhinotrachetis (BR) Virus in Porcine Kidney Tissue Culture." *Proc Soc. Exp. Biol. Med* 97:680-683	
	362	**Scott, Jamie K. and George P. Smith,** "Searching for Peptide Ligands with an Epitope Library," Science 249:386-388 (1990)	
	363	**Seliger et al.,** "TAP off – tumors on," Immunol. Today 18: 292-299 (1997).	
	364	**Sharma and Graham** (1982) "Influence of Material Antibody on Efficacy of Embryo Vaccination with Cell-Associated ans Cell-Free Marek's Disease Vaccine." *Avian Dis.* 26:860-870	
	365	**Sheu et al.** (1995) "Deletion or alteration of hydrophobic amino acids at the third transmembrane domains of Hepatitis B Surface antigen enhances its production in Escherichia coli." 160(2):179-184	
	366	**Shouval et al.** (1994) "Improved immunogenicity in Mice of a mammalian cell-derived recombinant hepatitis B Vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines." *Vaccine* 12(15):1453-1459	
	367	**Sizemore et al.,** "Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization," Science 270:299-302 (1995)	
	368	**Smith,** "In Vitro Mutagenesis," Ann. Rev. Genet. 19:423-462 (1985)	
	369	**Sokolic et al.** (1996) "A Bicistronic Retrovirus Vector Containing a Picornavirus InternationalRibosome Entry Site Allows for Correct of X-Linked CGD Selection for MDR1 Expression." *Blood* 87:42-50	
	370	**Soong et al.** (1998) "DNA shuffling as a tool to evolve desired retrovial phenotypes." Abstracts of papers presented at the 1998 meeting on Gene Therapy, p. 228 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, September 23-27, 1998	
	371	**Soong et al.** (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstract #97, Programs & Abstracts, 1st Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 28-31, 1998	
	372	**Soong et al.** (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstracts of papers presented at the 1998 meeting on Retroviruses, Cold Springs Harbor Laboratory, Cold Spring Harbor, New York, May 26-31, 1998	
	373	**Sosnovtsev et al.** (1998) "Cleavage of the Feline Calicivirus Capsid Precurrsor Is Mediated by a Virus-Encoded Proteinase." *J. Virol* 72:3051-3059	
	374	**Srinivasan et al.** (1987) "Molecular characterization of human immunodeiciency virus from Zaire." *Gene* 52:71-82	
	375	**Stemmer** (1991) "A 20-Minute ethidium bromide/high-salt extraction protocol for plasmid DNA." *BioTechniques* 10(6): 726	
✓	376	**Stemmer** (1994) *Nature* 370:389	

Examiner Signature	T. Wisnewski	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	377	**Stemmer** (1996) "DNA sequence evolution by sexual PCR." Experientia (Basel) 52(ABSTR): A25	
	378	**Stemmer** (1998) "Directed evolution of proteins, pathways, episomes and viruses by DNA shuffling," FASEB Journal 12(8): A1303	
	379	**Stemmer and Soong, (1999)** "Molecular breeding of viruses for targeting and other clinical properties," Tumor Targeting 4:1-4	
	380	**Stemmer et al.** (1991) "Expression of antibody Fv Fragments specific for a heavy metal chelate (indium-EDTA) in E. coli." Journal of Cellular Biotechnology Supplement 0 (15 PART G):217	
	381	**Stemmer et al.** (1992) "Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis." BioTechniques 13(2): 214, 216, 218-220	
	382	**Stemmer et al.** (1993) "Increased antibody expression from Escherichia coli through wobble-base library mutagenesis by enzymatic inverse PCR>" Gene 123(1): 1-7	
	383	**Stemmer et al.** (1993) "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR>" Biotechniques 14(2): 256-265	
	384	**Stemmer et al.** (1997) "Molecular evolution of genetic vaccines by DNA shuffling." FASEB Journal 11(9): A1124 17TH Intarnational Congress of Biochem . . .San Francisco, CA USA (2/24-29,)	
	385	**Stemmer et al.**,(1995) "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides," Gene 164:49-53	
	386	**Stemmer,** "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution," Proc. Natl. Acad. Sci. USA 91:10747-10751 (1994)	
	387	**Stemmer, W.P.C.**, "Rapid evolution of a protein in vitro by DNA shuffling," Nature 370:389-391 (1994)	
	388	**Stemmer, W.P.C.**, "Searching Sequence Space," Biotechnology 13:549-553 (1995)	
	389	**Stemmer, W.P.C.**, "Sexual PCR and Assembly PCR," The Encyclopedia of Molecular Biology, VCH Publishers, New York pp. 447-457 (1996)	
	390	**Stemmer, W.P.C.**, "The Evolution of Molecular Computation," Science 270:1510 (1995)	
	391	**Stern et al.**, "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells," Proc. Nat'l. Acad. Sci. USA 87:6808 (1990)	
	392	**Stohwasser et al.**, "Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon -γ-modulated proteasome subunits," Eur. J. Immunol. 27:1182-1187 (1997)	
	393	**Subbarao et al.** (1993) Rescue of an Influenza A Virus Wild-type PB2 Gene and a Mutant Derivative Bearing a Site-Specific Temperature-sensitive and Attenuating Mutation." *J. Virol.* 67:7223-7228	
	394	**Sugimoto et al.** (1994) "Characteristics of an attenuated vaccinia virus strain, LC16m0 and It's recombinant virus vaccines." *Vaccine* 12:675-681	
	395	**Sugimoto et al.** (1995) Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human a-Galactosidase A for Gene Therapy of Febry Disease." *Human Gene Ther* 6:905-915	
	396	**Tahara et al.**, "IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts," Human Gene Therapy 6:1607 (1995)	
✓	397	**Tan et al.**, "Characterizationof Recombinant Extracellular Domain of Human Interleukin-10 Receptor," J. Biol. Chem. 270:12906 (1995)	

Examiner Signature	T. Wurendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TW	398	**Tang et al.** (1992) "Genetic immunization is a simple method for eliciting an immune response." *Nature* 356:152	
	399	**Tang et al.**, "Vaccination onto bare skin," Nature 388: 729-730 (1997).	
	400	**Tano et al.** (1990) *Proc. Nat'l Acad Sci USA* 87:686-690	
	401	**Tartagila et al.** (1992) "NYVAC: A Highly Attenuated Strain of Vaccinia Virus." *Virology* 188:217-232	
	402	**Tascon, Richard E. et al.**, "Vaccination against tuberculosis by DNA injection," Nat. Med. 2:888-92 (1996)	
	403	**Taylor et al.**, "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA," Nucl. Acids Res. 13:8765-8787 (1985)	
	404	**Taylor et al.**, "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA," Nucl. Acids Res. 13:8749-8764 (1985)	
	405	**Thierfelder et al.** "Requirement for Stat4 in interleukin-1-2-mediated responses of natural killer and T cells", Nature 382:171 (1996)	
	406	**Todd** (1974) "Development of Intranasal Vaccination for the Immunization of Cattle Against infectious Bovine Rhinotrachetis." *Can. Vet J.* 15:257-259	
	407	**Trudel et al.**, "pGATA: A Positive Selection Vector Based on the Toxicity of the Transcription Factor GATA-1 to Bacteria," Biotechniques 20:684-693 (1996).	
	408	**Tytgat, G.N.**,"Review article: practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer,"Aliment. Pharmacol. Ther. 12(1):123-8 (1998)	
	409	**Ugen et al.** (1994) "DNA inoculation as a novel vaccination method against retroviruses with rheumatic disease associations." *Immunol. Res.* 13:154-162.	
	410	**Ulmer et al.** (1993) "Heterologous protection against influenza by injection of DNA encoding a viral protein." *Science* 259:1745	
	411	**Ulmer et al.** (1996) "ELI's coming: expression library immunization and vaccine antigen discovery." *Trends im Microbiology* 4(5):170-171	
	412	**Valle amd Falgout** (1998) "Mutagenesis of the NS3 Protease of Dengue Virus Type 2." *J. Virol* 72:624-632	
	413	**van Dinten et al.** (1997) "An Infectious arterivirus cDNA clone." *Proc. Nat'l Acad. Sci USA*94:991-996	
	414	**VanCott et al.**, "Antibodies with Specificity to Native gp120 and Neutralization Activity against Primary Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp160," J. Virol. 71:4319-4330 (1997)	
	415	**Vassilev et al.** (1997) "Authentic and Chimeric Full-length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yeild Infectious Transcrips." *J. Virol* 71:471-487	
	416	**Velzing et al.** (1999) "Induction of protective immunity against Dengue virus type 2." *Vaccine* 17:1312-1320	
	417	**Villinger et al.**, "Comparative Sequence Analysis of Cytokine Genes from Human and Nonhuman Primates," J. Immunol. 155:3946-3954 (1995)	
	418	**Walther et al.** (1996) "Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting." *J. Mol. Med.* 74:379-392	

Examiner Signature	T. Wisendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

TLW	419	**Wang et al.** (1993) "DNA inoculation induces cross clade anti-HIV-1 responses." *Annals New York Acad. Sci* 186-196	
	420	**Wang et al.** (1993) "Gene inoculation generates immune responses against human deficiency virus type 1." *Proc. Nat'l Acad. Sci. USA* 90:4156-4160	
	421	**Walunas et al.**, "CTLA-4 Can Function as a Negative Regulator of T Cell Activation," Immunity 1:405 (1994)	
	422	**Wells et al.**, "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," Gene 34:315-323 (1985)	
	423	**Wells et al.**, "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," Phil. Trans. R. Soc. Lond. A317:415-423 (1986)	
	424	**Wermeille, Joel et al.**, "The eradication treatments of Helicobacter pylori," Pharm. World Sci. 20:1-17 (1998)	
	425	**Whelan et al.** (1995) "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones." *Proc. Nat'l. Acad. Sci. USA* 92:8388-8392	
	426	**Whitacre et al.**,"Treatment of Autoimmune Disease by Oral Tolerance to Autoantigens," Clin. Immunol. Immunopathol. 80: S31-9 (1996).	
	427	**Wiertz et al.**, "SEC61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction," Nature 384: 432 (1996).	
	428	**Wiertz et al.**, "The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class 1 Heavy Chains from the Endoplasmic Reticulum to the Cytosol," Cell 84: 769-779 (1996).	
	429	**Williams et al.** (1993) "Genetic Infection Induces Protective In Vivo Immune Response." *DNA & Cell Biology* 12(8):675-683	
	430	**Williams et al.** (1994) "Immunotherapeutic strategies targeting rheumatiod synovial T-cell receptors by DNA inoculation." *Immunol. Res* 13:145-153	
	431	**Winther et al.** (1998) "Viral-Induced Rhinitis." *Am J. Rhinol* 12:17-20	
	432	**Wisniak et al.** (1974) "Hydrogen Solubililty in Joboba Oil." *JAOCA* 51:482-485	
	433	**Wloch et al.**, "The Influence of DNA Sequence on the Immunostimulatory Properties of Plasmid DNA Vectors," Hum. Gene Ther. 9:1439-1447 (1998)	
	434	**Woody, Mary Alice et al.**, "Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model," Vaccine 15(2):133-139 (1997)	
	435	**Wright et al.** (1998) "Humane endpoints are an objective measure of morbidity in Venezelan encephalomyelitis virus infection of mice,' *Arch Virol* 143:1155-1162	
	436	**Xiang et al.** (1994) "A Simple method to test the ability of individual viral proteins to induce immune responses." *J. Virological Methods* 47:103-116	
	437	**Xiang, Z. et al.**, "Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines," Immunity 2:129-135 (1995)	
	438	**Yanagi et al.** (1997) "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee." *Proc Nat'l Acad. Sci. USA* 94:8738-8743	
	439	**Yanagi et al.** (1999) "In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone." *Proc. Nat'l Acad. Sci USA* 96:2291-2295	
✓	440	**Yao et al.** (1998) "Generation of Mutant Infectious Bursal Disease Virus That Does Not Cause Bursal	

Examiner Signature	T. Wilson	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**09/724,869**
	Filing Date	**November 28, 2000**
	First Named Inventor	**Juha Punnonen**
	Group Art Unit	**1627**
(use as many sheets as necessary)	Examiner Name	**Unassigned**
	Attorney Docket Number	**02-030310US**
	Date Submitted	**May 21, 2002**

		Leaions." *J. Virol.* 72:2647-2654	
JW	441	**Yu et al.** (1995) "Functional cDNA Clones of the Human Respiratory Syncytial (RS) Virus. . ." *J. Virol* 69:2412-2419	
	442	**Zamvil, Scott S. and Lawrence Steinman**, "The T Lymphocyte in Experimental Allergic Encephalomyelitis," Ann. Rev. Immunol. 8:579-621 (1990)	
	443	**Zanelli et al.** (1993) "Epitope mapping of human thyroid peroxidase defined seven epitopes reconized by sera from patients with thyroid pathologies." *Cell. & Mol Biol.* 39(5):491-501	
	444	***Zhang, J. et al.**, "Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening," Proc. Natl. Acad. Sci. USA 94:4504-4509 (1997)*	
	445	**Zhong et al.** (1998) "Idenification and Characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," *J. Virol.* 72:9365-9369	
	446	**Zhong, Weimin et al.**, "Therapeutic passive vaccination against chronic Lyme disease in mice," Proc. Nat'l. Acad. Sci. USA 94:12533-12538 (1997)	
	447	**Zoller and Smith**, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," Nucl. Acids res. 10:6487-6500 (1982)	
	448	**Zoller and Smith,** "Oligonucleotide-Directed Mutagenesis: A Simple Method using Two Oligonucleotide Primers and a Single-Stranded DNA Template," Methods in Enzymol. 154:329-350 (1987)	
	449	**Zoller and Smith,** "Oligonucleotide-Directed Mutagenesit of DNA Fragments Cloned into M13 Vectors," Methods in Enzymol. 100:468-500 (1983)	
	450	**Zou et al.** (1995) "Structure-function analysis of the p35 subunit of mouse interleukin 12." *J. Bio. Chem.* 270(11):5864-5871	
	451	**Zuschek et al.** (1961) "Immunogenicity of 2 Infectious Bovine Rhinotracheitis Vaccines." *J. Am. Vet. Med. Assoc.* 139"236-237	
✓	452	**Zygraich et al.** (1974) "In Vivo and In Vitro Properties of a Temperature Sensitive Mutant of Infectious Bovine Rhinotracheitis Virus." *Res. Vet. Sci.* 16:328-335	

Examiner Signature	T. Wessendorf	Date Considered	9/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.